Samarium lexidronam pentasodium
As of the edition of 20 October 2026, Samarium lexidronam pentasodium is a small molecule: marketed, first approved in 1997 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1998
- Kind
- Small molecule
- Brand name
- Quadramet
- First approved
- 28 March 1997 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Cis Bio; 2 holders in all
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Cis Bio | Applicant | 1998 to now |
| Lantheus Medical Imaging | Acquired holder | 2014 to now |
| Cytogen | Originator | 1997 to 2014 |